Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
Statistics in Medicine
|
March 7, 2014
Weighted profile likelihood-based confidence interval for the difference between two proportions with paired binomial data
Vivek Pradhan, Krishna K Saha, Tathagata Banerjee, et al.
Journal of Crohn'S & Colitis
|
August 24, 2023
Alternative Endoscopy Reading Paradigms Determine Score Reliability and Effect Size in Ulcerative Colitis
Walter Reinisch, Vivek Pradhan, Saira Ahmad, et al.
Clinical Therapeutics
|
April 18, 2016
Safety, Pharmacokinetic, and Pharmacodynamic Evaluation After Single and Multiple Ascending Doses of a Novel Selective Androgen Receptor Modulator in Healthy Subjects
Indranil Bhattacharya, Sanela Tarabar, Yali Liang, et al.
Archives of Dermatological Research
|
March 12, 2025
Correction: Ritlecitinib, a JAK3 /TEC inhibitor, modulates the markers of celiac autoimmunity in alopecia areata and vitiligo patients
Rok Seon Choung, Jyoti Ramakrishna, Vivek Pradhan, et al.
Archives of Dermatological Research
|
January 18, 2025
Ritlecitinib, a JAK3 /TEC inhibitor, modulates the markers of celiac autoimmunity in alopecia areata and vitiligo patients
Rok Seon Choung, Jyoti Ramakrishna, Vivek Pradhan, et al.
Journal of the American Academy of Dermatology
|
April 10, 2022
Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study
Christopher Tehlirian, Ravi Shankar P Singh, Vivek Pradhan, et al.
British Journal of Clinical Pharmacology
|
June 3, 2026
A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-07261271 in healthy participants
Srividya Neelakantan, Christopher Banfield, Kenneth Hung, et al.
Therapeutic Advances in Gastroenterology
|
February 13, 2026
Efficacy and safety of the interleukin-10-fragment F8 fusion protein PF-06687234 as add-on therapy to infliximab in patients with active ulcerative colitis: a randomized, phase IIa clinical trial
Stefan Schreiber, Silvio Danese, Séverine Vermeire, et al.
The British Journal of Dermatology
|
March 27, 2023
Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study
Megan N Landis, Stacy R Smith, Gabriel Berstein, et al.
The Lancet. Rheumatology
|
January 27, 2024
Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study
Christopher Tehlirian, Elena Peeva, Elizabeth Kieras, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
Statistics in Medicine
|
March 7, 2014
Weighted profile likelihood-based confidence interval for the difference between two proportions with paired binomial data
Vivek Pradhan, Krishna K Saha, Tathagata Banerjee, et al.
Journal of Crohn'S & Colitis
|
August 24, 2023
Alternative Endoscopy Reading Paradigms Determine Score Reliability and Effect Size in Ulcerative Colitis
Walter Reinisch, Vivek Pradhan, Saira Ahmad, et al.
Clinical Therapeutics
|
April 18, 2016
Safety, Pharmacokinetic, and Pharmacodynamic Evaluation After Single and Multiple Ascending Doses of a Novel Selective Androgen Receptor Modulator in Healthy Subjects
Indranil Bhattacharya, Sanela Tarabar, Yali Liang, et al.
Archives of Dermatological Research
|
March 12, 2025
Correction: Ritlecitinib, a JAK3 /TEC inhibitor, modulates the markers of celiac autoimmunity in alopecia areata and vitiligo patients
Rok Seon Choung, Jyoti Ramakrishna, Vivek Pradhan, et al.
Archives of Dermatological Research
|
January 18, 2025
Ritlecitinib, a JAK3 /TEC inhibitor, modulates the markers of celiac autoimmunity in alopecia areata and vitiligo patients
Rok Seon Choung, Jyoti Ramakrishna, Vivek Pradhan, et al.
Journal of the American Academy of Dermatology
|
April 10, 2022
Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study
Christopher Tehlirian, Ravi Shankar P Singh, Vivek Pradhan, et al.
British Journal of Clinical Pharmacology
|
June 3, 2026
A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-07261271 in healthy participants
Srividya Neelakantan, Christopher Banfield, Kenneth Hung, et al.
Therapeutic Advances in Gastroenterology
|
February 13, 2026
Efficacy and safety of the interleukin-10-fragment F8 fusion protein PF-06687234 as add-on therapy to infliximab in patients with active ulcerative colitis: a randomized, phase IIa clinical trial
Stefan Schreiber, Silvio Danese, Séverine Vermeire, et al.
The British Journal of Dermatology
|
March 27, 2023
Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study
Megan N Landis, Stacy R Smith, Gabriel Berstein, et al.
The Lancet. Rheumatology
|
January 27, 2024
Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study
Christopher Tehlirian, Elena Peeva, Elizabeth Kieras, et al.
Page
of 3